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Parkinson 's dis ease is a slowl y progressive, neurodegenerative di sorder
a ffec t ing one in 1,000 of th e gen eral population ; its in cid e nce increases with age ,
but the ca use remains unknown . The di sease is characte r ized pathologically by a
loss of neurons fr om th e pigmented subs ta n t ia nigra par s co mpacta , and a tr iad
of ph ysical symptoms of rigidity, tremor, and bradykin esia or akinesia . T h us the
clini cal cond ition of Parkinson's di sease is a rather complex disorder with a
variety of physical symp toms due to neuronal damage in a num ber of brain
regi ons. Additional brain regions a lso affec te d in clinical Parkinson 's di sease
include the ventra l tegmental area, locu s coer u leus, serotonergic dorsal raphe
syste m, and th e dorsal motor nucleus of the vagus ( I) . Furthermore, it has bee n
suggeste d th at damage to these var ious regions of the bra in leads to a variety of
motor and mental di sorders (depression a nd dementia) that are specific to th e
damag e in eac h of these neuronal syste ms (2) . Loss of norep inep hr ine may lea d
to depression ; the incidence of depression va r ies betwee n 20 to 90 percent in
Parkinson 's di sea se, and many of th ese patients show favorab le responses to
tricyclic antidepressants.
Recently, several individuals developed a Parkinson-like d iso rde r followin g
intravenous administration of MPTP (l -methy l-4-phenyl -1,2,3,6-tetrah ydropy-
ridine). MPTP is create d as a byproduct in the synthesis of a synthetic heroin
l -m ethyl-4-phenyl-4-propionoxypiperidine (MPP P). Ad mixed with varying
amou nts of MPPP, MPTP was illicitly so ld as a new type of he ro in (3) in a limited
region of northern California. Man y users developed a Parkinson-like disorder
with bradykinesia, rigidity, tremor, flexed posture , loss of postu ral reflexes, an d
drooling followin g intravenous administ ration of MPTP (3-5) . Results of MPTP
use in humans demonstrated that this co mpound ca n closely reproduce th e
symptomato logy of idiopathic Parkinson's di sease, and may p rovid e a new tool
for in vestigating ba sic neurobiological and clinical aspects of Parkinson's
disease, probably leading to better therapeutic approach es th an what has been
available so far.
MPTP AND PARKINSON'S DISEASE
A severe loss of pigmented nerve ce lls in the subs ta n tia nigra pa rs compacta
and low levels of homovanillic ac id in the cerebrospinal fluid have bee n reported
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in patients with MPTP-induced Parkinsonism (4). The clinical sig ns and symp-
toms of Parkinsonism in th ese patients could be ameliorated by ad min istration
of L-dopa (3,4); some patients experienced typical treatment-related co mplica-
tions of long-term L-dopa therapy such as deterioration , peak-dose d yski nesia ,
and " on-o ff " phenomena (5).
Furthermore, intravenous administration of MPTP ha s been reported to
produce Parkinson-like sympto ms in non-human primat es (6-8), inclu d ing
bradykinesia, postural tremor, and muscular rigidity; L-dopa th erap y amelio-
rates these problems (6). MPTP treatment resulted in decreased release of
dopamine in the striatum, and dopamine accumulation in swo llen axons in the
nigrostriatal pathway just rostral to the substantia nigra (6 ,9, I0), foll owed by
extensive loss of nerve cells in the pars compacta of th e substa ntia nigra ( I I), and
a marked reduction in the dopamine contents of th e striatum. MPTP has been
also shown to produce degeneration of the nigrostriatal dopam inergic syste m in
mice (12,13), as well as other monoaminergic systems (13 ,14).
In humans, dopamine levels in the striatum decrease with age (15), bu t the
decrease is much sharper in humans with Parkinson's di sease (16). McGeer and
colleagues (17) showed that substant ia nigra neurons diminish in number wit h
age , and may demonstrate qualitative differences in appearance as well , suc h as
sh r ive ling . These studies suggest that dopamine neurons undergo age-related
changes that lead to diminished levels and synthesis of dopamine in ne r ve
terminals, accompanied by ce ll loss in th e substant ia nigra. More rec ently, it has
been shown that MPTP given to aging mice produces more severe ph ysica l an d
morphological alterations (18) that are not seen in young ad u lt mice. The
physical symptoms include bradykinesia , rigidity, and an initial resting t remor of
th e whole body. Neuroanatomically, there is evidence of changes in th e ventral
tegemental area (mesolimbic dopaminergic system that sends d opamine proj ec-
tions to the nucleus accumbens and the olfactory tubercle , i.e., th e limbic system)
as well as the locus coeruleus (noradrenergic cell group that sends project io ns to
the cerebral cortex, cerebellum, and hippocampus). All th ese stud ies suggest
that MPTP-induced animal models in non-human primates and mice may
provide insight into the mechanism and cause of neuronal degeneration.
MPTP AND MAO INHIBITORS
The oxidative metabolism of MPTP to its l-methyl-4-phenyl pyridinium
analog (MPP+) is a critical feature in the neurotoxic process (19) . Furthe rmore ,
th e monoamine oxidase (MAO) inhibitor, pargyline, and th e specific MAO-B
inhibitors (deprenil, AGN-1133, AGN-1135), can prevent the conversion of
MPTP to MPP+, while the spec,ific MAO-A inhibitor, c1orgylin e , ha s no suc h
effect (20-24). These observations suggest that MAO-B is responsible fo r th e
oxidative metabolism of MPTP to its pyridinium analog. More recently, using
monoclonal antibodies to MAO-A and MAO-B in non-human primates, West-
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lund, et al (25) reported MAO-A positive cell bodies in neuro ns of ca techola-
mine cell groups, whi le MAO-B cell bodies were observed in seroto nergic raphe
nuclei, including raphe dorsalis and nucleus ce nt ra lis super ior. T hese findings
suggest that MPTP ma y be taken up into serotonergic neurons, metabolized to
MPP +, released, and further tak en up by th e nigrostriatal and th e ventra l
tegmental area dopaminergic systems, where damage to th ese neurons then
occurs.
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